Navigation Links
Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Date:10/1/2009

t cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA®, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements. These include statements concerning the potential for TELCYTA to treat NSCLC, and the effectiveness of TELCYTA in combination with carboplatin and paclitaxel and as maintenance therapy in NSCLC patients. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including the risks associated with clinical trials and the interpretation of resulting data. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended June 30, 2009. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
6. Telik Announces Presentation at ASCO Annual Meeting
7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ... drug delivery systems, today announced that its Chairman and ... at the Piper Jaffray 26th Annual Healthcare Conference at ... on Tuesday, December 2, 2014. The ... a "live" listen only Webcast. To listen, please go ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
(Date:11/24/2014)... SAN DIEGO , Nov. 24, 2014  Arena Pharmaceuticals, ... is scheduled to present a corporate overview and update at ... Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 ... New York . A live ... investor relations section of Arena,s website at www.arenapharm.com . ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
... N.J., March 8, 2012  Janssen Research & Development, ... Phase 3 study of ZYTIGA® (abiraterone acetate) plus ... symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) ... Study COU-AA-302 is an international, randomized, double-blind, placebo ...
... AMSTERDAM, March 8, 2012  Leading events organiser UBM Live ... announced an addition to the CPhI Japan events line-up ... Sight Exhibition Centre from 21-23 March, 2012. The Pharmatech ... technology for the Pharma, biopharma, veterinary and medical industries, ...
Cached Medicine Technology:Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 2Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 3Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 4Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 5Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 6New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 2New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 3
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
(Date:11/26/2014)... 26, 2014 Sonru, the video interviewing ... Chief Operating Officer and Chief Marketing Officer, in addition ... , Jeff Jones has been appointed as Chief ... takes the role of Chief Marketing Officer. , Mr ... whose 25-year career includes senior roles with The Walt ...
(Date:11/26/2014)... November 26, 2014 Call 866-997-4948 (Us-Canada ... or email the details on sales(at)researchmoz(dot)us , Researchmoz.us ... drug discovery market 2014" with deep study of the ... result of high blood sugar. The global glucose monitoring ... to the growing number of diabetics in the world. ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 For those with ... new LES MILLS BODYPUMP™ classes at the University ... the workout they've been looking for. The 45- 60 minute ... Anschutz Health and Wellness Center fitness club memberships. , LES ... workouts are fast-paced and are aimed at fast results ...
(Date:11/26/2014)... 26, 2014 Sonoran Vein and ... received the Distinguished Preceptorship Award from The ... role in the advancement of nurse practitioners. The ... individual who had made a significant contribution toward ... American Association of Nurse Practitioners (AANP) is the ...
Breaking Medicine News(10 mins):Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2
... an efficient, effective way to analyze wounds from bullets and ... the March issue of Radiology . "The ... care and aid in both military and civilian forensic investigations," ... from the Uniformed Services University in Bethesda, Md. U.S. ...
... Extremely obese people had a significantly greater chance of dying ... that became a pandemic last winter, a new study reports. ... with H1N1 flu during the first four months of 2009 ... three-fold increased risk for death. Extreme obesity is defined ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, Jan. ... the risk of autism in the second child, new research ... within a year of their older sibling. Babies conceived within ... their older sibling were also at a heightened risk of ...
... HealthDay Reporter , MONDAY, Jan. 10 (HealthDay News) -- Widespread ... a 5 percent drop in available nursing home beds across ... research reveals. "The country,s minority population is aging at ... lead author Zhanlian Feng, an assistant professor of community health ...
... is well known that pain is a highly subjective experience. ... depending on distractions and mood. A paper in the ... cautionary note on measuring perceived pain in research. There ... symptoms other than pain, but because of the subjectivity in ...
... report a gene therapy strategy that improves the condition ... Beta Thalassemia. The gene correction involves using unfertilized ... embryonic stem cell lines. Some of these stem cell ... thus be used for transplantation-based treatments of the same ...
Cached Medicine News:Health News:CT helps identify bullet trajectories 2Health News:Closely Spaced Pregnancies Might Up Autism Risk: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 3Health News:Does it hurt? 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: